Global Pharmaceutical Regulation: Comparative Frameworks and Operations

1. Introduction

The pharmaceutical industry operates within an increasingly complex and interconnected regulatory environment designed to ensure the safety, efficacy, and quality of medicinal products worldwide. Regulatory affairs (RA) is a key function of the pharmaceutical industry, overseeing the development, approval, manufacturing, and ongoing monitoring or post-marketing surveillance of pharmaceutical agents to ensure they meet ever-evolving regulatory standards. As healthcare challenges become more global in nature and medical innovations advance at an unprecedented pace, regulatory affairs play an essential role in ensuring consistency, stability, and compliance with international best practices and standards. Regulatory frameworks must therefore continue to evolve while maintaining their fundamental role in protecting public health [1].

The last decade has witnessed significant transformations in regulatory approaches, driven by technological advancements, emerging health threats, and the growing need for international collaboration [2]. These changes include the adoption of expedited review pathways, reliance models, the integration of real-world evidence, and increased emphasis on post-marketing surveillance systems capable of proactive risk detection. The COVID-19 pandemic and the emergence of the COVID-19 vaccines revealed the importance of cross-border regulatory collaboration, catalyzing joint reviews, emergency use authorizations, and digital innovation in regulatory operations.

Beyond compliance, regulatory affairs professionals facilitate drug approvals by navigating complex submission processes, addressing regulatory requirements across different regions, and ensuring timely market entry. They also serve to align global dossiers across regions to meet the essential needs of medical humanity. Furthermore, post-marketing surveillance mechanisms overseen by Regulatory Affairs (RA) help identify safety signals, enabling proactive risk management and ongoing product life cycle oversight. International collaboration amongst regulatory authorities across countries brings several advantages, including better access to affordable medications, the exchange of expertise, alignment of regulatory standards, and initiatives to strengthen regulatory capabilities [3].

While the literature is replete with of the United States Food and Drug Administration (FDA) [4,5,6,7], the European Medicines Agency (EMA) [6,7,8], and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) [3,9], this paper further examines the critical roles of regulatory affairs in pharmaceutical development and marketing, emphasizing the importance of international collaboration and harmonization in an increasingly interconnected global medical ecosystem. It also compares both established and emerging regulatory authorities across regions exploring how different regulatory authorities approach these challenges while considering regional requirements and populational heterogeneity.

2. Global Regulatory Landscape

2.1. Global Regulatory Authorities

Global markets have undergone significant evolution in recent decades, characterized by an unprecedented expansion of cross-border trade and investment activities, including healthcare. This heightened interdependence among nations underscores the necessity for robust regulatory frameworks to manage risks and promote international relations effectively. Regulatory authorities play a central role in these systems, ensuring safety, uniformity and stability, and compliance across jurisdictions.

2.1.1. Established Major Regulatory Authorities

Amongst several other agencies, the FDA, PMDA, and the European medicines regulatory network – coordinated through the EMA in partnership with national competent authorities (NCAs) in EU/EEA Member States - constitute the principal regulatory bodies governing clinical trials, market authorization, and post-marketting surveillance worldwide. These systems, encompassing the United States, Europe, and Japan, maintain distinctive regulatory frameworks that shape the landscape of pharmaceutical drug development and approval processes. Together, they represent some of the most comprehensive pharmaceutical regulatory approaches, with highly structured review processes and international impact [10].

• The US Food and Drug Administration (FDA)

The Food and Drug Administration (FDA), one of the oldest regulatory bodies, was established to address safety concerns surrounding medical supplies and patent medicines, leading to the enforcement of the Pure Food and Drug Act of 1906 [11]. Initially, its authority was limited to preventing the adulteration and misbranding of food and drugs, as outlined before the Federal Food, Drug, and Cosmetic (FD&C Act) of 1938 [12]. As an example, the thalidomide-related birth defects prompted the introduction of the Kefauver-Harris Amendments, which mandated premarket approval and required evidence of both safety and effectiveness [13]. These reforms shaped the pre-market regulatory framework still in use today. The FDA enforces laws and guidelines that form the basis of its regulatory authority, primarily outlined in the FD&C Act [14]. The FDA is responsible for protecting public health by ensuring the safety and efficacy of drugs, medical devices, food, cosmetics, and tobacco products, advancing medical innovations, providing science-based information to the public, and supporting national counterterrorism efforts [15,16].

2.

Europe’s medicines regulatory network: the European Medicines Agency (EMA) and national competent authorities (NCAs).

Medicines regulation in Europe is delivered through a coordinated network of the European Medicines Agency (EMA), the European Commission, and national competent authorities (NCAs) in EU/EEA Member States. Established in 1995, EMA fosters scientific excellence in the evaluation and supervision of medicines, and supports timely patient access to innovative therapies, through its adaptive pathways’ initiative [17,18]. In the centralized procedure, the EMA is responsible for the scientific evaluation of marketing authorization applications; once granted by the European Commission, the centralized marketing authorization is valid in all EU Member States as well as Iceland, Norway, and Liechtenstein [19]. NCAs are primarily responsible for authorizing medicines that do not fall under the scope of the centralized procedure and may also be responsible for other activities related to medicinal products, including authorization of clinical trials [20,21]. In pharmacovigilance, EU law requires marketing authorization holders, NCAs, and EMA to operate pharmacovigilance systems, with overall safety monitoring operating through cooperation between Member States, EMA, and the European Commission [22].

Finland’s Finnish Medicines Agency (Fimea), provides an example of a national authority within the EU network, combining regulation, medicines information, and pharmacovigilance. Fimea regulates and develops the pharmaceutical sector and promotes the rational use of medicines by producing and providing drug information, while also overseeing pharmacovigilance nationally as part of the EU’s agency network [17,23]. Finland’s Kanta Prescription Centre stores all electronic prescriptions and associated dispensing notes in a central service, supporting medication safety and enabling comprehensive analyses of national prescription drug utilization [24,25].

Similarly, Sweden’s Medical Products Agency (Läkemedelsverket) is the national authority responsible for the regulation and surveillance of the development, manufacturing, and sale of medicinal products [26]. Sweden also maintains a National Prescribed Drug Register, established in 2005, which contains all prescribed drugs dispensed in pharmacies and provides a strong foundation for official statistics and real-world drug utilization research [27].

3.

Japan's Pharmaceuticals and Medical Devices Agency (PMDA)

The Pharmaceutical and Medical Device Agency (PMDA) is a Japanese regulatory agency governed by the Ministry of Health, Labour, and Welfare, recognized for its role in protecting public health by assuring the safety, efficacy and quality of pharmaceuticals and medical devices [28]. This agency was established and became functional on April 1, 2004, under the Law for the Pharmaceuticals and Medical Devices Agency, as a consolidation of the services of the Pharmaceuticals and Medical Devices Evaluation Center of the National Institute of Health Sciences (PMDEC), the Organization for Pharmaceutical Safety and Research (OPSR/KIKO), and parts of the Japan Association for the Advancement of Medical Equipment (JAAME) [29].

2.1.2. Emerging Major Regulatory Authorities

The BRIC countries (Brazil, Russia, India, and China) featured below constitute major emerging pharmaceutical markets distinguished by their large, fast-growing economies and significant regional influence, positioning them as increasingly important regulatory powers in the global pharmaceutical landscape [30]. In general, each agency of the BRIC countries regulates pharmaceutical and healthcare products in broad accordance to the framework of the FDA, PMDA, and EMA.

• China's National Medical Products Administration (NMPA)

The National Medical Products Administration (NMPA), previously known as the China Food and Drug Administration (CFDA), has its origins in the State Food and Drug Administration (SFDA). In March 2013, the SFDA was renamed and restructured as the CFDA, achieving the status of a ministerial-level agency [31]. Subsequently, as part of China's governmental reorganization, the NMPA experienced another transformation in March 2018, which involved its consolidation into the newly established State Administration for Market Regulation (SAMR) [31]. The National Medical Products Administration (NMPA) is responsible for regulating the safety, quality, registration, and post-marketing management of drugs, medical devices, and cosmetics, while also formulating policies, standards, and laws, overseeing professional qualifications, and engaging in international cooperation in these areas [31].

2.

Brazil's National Health Surveillance Agency (ANVISA)

The Brazilian Health Surveillance Agency (Agencia Nacional de Vigilancia Sanitaria – ANVISA) was established in January 1999 [32,33]. Its primary objective is to protect public health by managing risks associated with health-related goods and services. ANVISA’s main focus includes maintaining scientific standards, regulating, and inspecting products that may endanger health. Operating under the Brazilian National Health System (SUS), Anvisa is responsible for overseeing the production of health goods and healthcare services in both the public and private sectors [32,33]. Its duties include enforcing industry regulations, inspecting manufacturing practices, and registering and monitoring health products and procedures. Furthermore, ANVISA plays a significant role in the implementation of healthcare policies, such as pharmaceutical assistance, and in directing scientific research related to product development [32,33].

3.

India's Central Drugs Standard Control Organization (CDSCO)

The Central Drugs Standard Control Organization (CDSCO) serves as the central authority under the Drugs and Cosmetics Act, overseeing the approval of new drugs, clinical trials, drug standards, and quality control of imported drugs, and coordinating state drug control activities [34,35]. The Drug Controller General of India (DCGI) is responsible for approving licenses for specified categories of drugs such as blood and blood products, intravenous (IV) fluids, vaccines, and sera [34]. CDSCO’S mission is to safeguard public health in India by ensuring the safety, efficacy, and quality of drugs, cosmetics, and medical devices [34].

4.

Russia's Federal Service for Surveillance in Healthcare (Roszdravnadzor)

The Federal Service for Surveillance in Healthcare (Roszdravnadzor) was established by the President of the Russian Federation through Decree No. 314 dated March 9, 2004, "On the System and Structure of the Federal Executive Bodies," and serves as a federal executive body responsible for overseeing and regulating the healthcare system [36]. It also protects public health by ensuring safety and quality of medicines and medical devices manufactured in or imported into the Russian Federation.

2.1.3. Other Regulatory Authorities

While the FDA, the European medicines regulatory network (EMA and national competent authorities), PMDA, and emerging BRIC authorities command significant influence on the pharmaceutical landscape, other regulatory bodies also contribute essential regional perspectives and represent important pharmaceutical markets in their respective regions. Apart from Brazil's ANVISA, Argentina's ANMAT provides complementary South American representation as it follows a distinct regulatory approach and serves the second-largest pharmaceutical market in the region. This dual representation from South America mirrors our approach to Europe and North America, where the EU medicines regulatory network and the FDA provide established reference frameworks for large regional markets. The following regulatory authorities are therefore from regions not previously addressed, ensuring that all inhabited continents are represented in this global regulatory review:

• Argentina's National Administration of Drugs, Food and Medical Technology (ANMAT)

ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) of Argentina represents a key regulatory authority in South America, having been awarded the status of "Regulatory Authority of Regional Reference" by the Pan American Health Organization and gaining recognition as an ICH observer member in 2019 [37]. ANMAT's responsibilities extend beyond the scope of pharmaceutics, to include food safety, medical technology evaluation, and managing registration requirements for imported medical products, operating within a comprehensive regulatory framework that serves as a benchmark for neighboring countries [38].

2.

Australia's Therapeutic Goods Administration (TGA)

Australia's Therapeutic Goods Administration (TGA) stands as the preeminent regulatory authority for Oceania, with its influence extending throughout the Asia-Pacific region [39]. It also served as the 2022 chair of the International Medical Device Regulators Forum (IMDRF) and participated in international work-sharing initiatives with other major global regulatory authorities [39]. The TGA's core activities include the regulation of medicines, medical devices, blood and blood products, and vaping products, advertising; however, it does not regulate food, dietary supplements or veterinary drugs. The agency also oversees import and export controls to ensure consistent quality standards across Australia and neighboring Pacific countries [39].

3.

Selected African Regulatory Agencies (NAFDAC, SAHPRA, TMDA, EDA, Ghana’s FDA, MCAZ, ARP, Rwanda’s FDA)

The African Medicines Regulatory Harmonization (AMRH) initiative, launched in 2009, represents a landmark effort to address the continent’s challenges in ensuring access to quality, safe, and affordable medical products by promoting collaborative regional regulatory oversight and harmonized standards across the continent's eight Regional Economic Communities (RECs) [40]. Alongside this, the WHO benchmark, conducted with its Global Benchmarking Tool, evaluates regulatory systems against more than 250 indicators. Maturity Level 4, the highest level, signifies an advanced regulatory system committed to ongoing improvement. Maturity Level 3 indicates a stable, well-functioning, and integrated regulatory system [41]. Currently, out of 54 African countries, only 8 have achieved WHO Maturity Level 3 certification for their national medicines regulatory authorities [41] including:

• Nigeria (NAFDAC) – National Agency for Food and Drug Administration and Control
• South Africa (SAHPRA) - South African Health Products Regulatory Authority
• Tanzania (TMDA) - Tanzania Medicines and Medical Devices Authority
• Egypt (EDA) - Egyptian Drug Authority
• Ghana (FDA) – Food and Drugs Authority
• Zimbabwe (MCAZ) - Medicines Control Authority of Zimbabwe
• Senegal (ARP) - Agence Sénégalaise de Réglementation Pharmaceutique
• Rwanda (FDA) - Food and Drugs Authority

Nigeria's NAFDAC

NAFDAC merits focus as Nigeria's pharmaceutical market represents the largest in West Africa, accounting for 60% of the region’s market [42]. NAFDAC stands out among the eight WHO Maturity Level 3 certified regulatory authorities in Africa for its leadership in regional pharmaceutical regulation, and for overcoming severe challenges with counterfeit medications [43]. Another notable success was the pioneering of the Mobile Authentication Service (MAS), which allows consumers to verify product authenticity via short message service, otherwise known as SMS [44,45]. NAFDAC has also appointed accredited laboratories in China and India, to effect pre-shipment analysis and certification of drugs and pharmaceutical supplies coming into Nigeria [43]. Overall, the agency regulates and controls importation, exportation, manufacture, advertisement, distribution, sale and use of food, drugs, cosmetics, medical devices, bottled water, Chemicals and detergents [46].

2.2. Harmonization Initiatives and Comparative Regulatory Frameworks

2.2.1. Global Harmonization Efforts

Despite the local advances made in the regulatory landscape, there is an ongoing demand for global harmonization of science-based standards to streamline drug development and evaluation to enhance product quality, safety, and efficacy globally. In recent years, steps have been taken to harmonize and streamline application requirements across different countries through the establishment of several initiatives aimed at minimize the need for additional (and sometimes redundant) clinical trials, reduce costs, address disparities in safety monitoring systems and access to healthcare, and facilitating distribution of drugs while ensuring their safety and efficacy of the pharmaceutical agents.

The International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH) was established in 1990 [47]. It was designed to achieve greater harmonisation worldwide to ensure that safe, effective, and high-quality medicines are developed, and registered and maintained in the most resource-efficient manner whilst meeting high standards [47]. ICH has six founding members: US, EU, Japan, Canada, Swissmedic, and WHO [48]. The ICH includes standing regulatory members Health Canada, Canada; Swissmedic, Switzerland along with standing observers, including the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the WHO [49]. This harmonization has reduced duplication of clinical trials and procedures, lowering bureaucracy and shortening the time to market for new drugs [50].

2.2.2. Regional Harmonization Networks

Nations around the world often participate in a variety of regional harmonization networks that support and reinforce the global harmonization efforts. Regional harmonization can increase the efficiency of regulatory authorities by drawing from a shared pool of resources and expertise. Less-resourced National Regulatory Authorities (NRAs) see harmonization as a way to enhance collaboration, strengthen decision-making, share resources, reduce duplication, and improve public health outcomes [50].

2.3. Comparative Analysis of Regulatory Authorities

Regulatory systems vary considerably in their legal mandates, operational frameworks, review models, and degree of alignment with international standards. To characterize these differences systematically, Table 1 provides a comparative overview of core regulatory features across a set of established (FDA, EMA, PMDA) and emerging (NMPA, ANVISA, CDSCO, Roszdravnadzor) agencies. For a detailed version including twenty feature comparisons and explanatory descriptions, see Table S1. The features assessed span pre- and post-market regulatory requirements, scientific and procedural standards, and engagement with global harmonization initiatives, thereby offering a multidimensional perspective on the evolving global regulatory landscape.

3. Drug Development and Approval Process

3.1. Clinical Trial Oversight

3.1.1. Global Clinical Trial Standards

As a crucial process in drug development, the role of clinical trials cannot be overstated. Clinical trials ensure novel drugs are rigorously tested for efficacy and safety while adhering to ethical standards. Global frameworks such as the Belmont Report have become foundational practices held by clinical researchers and pharmaceutical industries when conducting studies involving human subjects to protect study participants [62]. Other important global standards include the International Ethical Guidelines for Biomedical Research Involving Human Subjects issued by the Council for International Organizations of Medical Sciences [63] and International Council for Harmonisation (ICH) and Guideline for Good Clinical Practice (GCP). These guidelines are globally recognized and are upheld as a tool for guiding clinical trial processes for new medicines [64,65].

3.1.2. Innovation in Clinical Trial Regulation

Innovative approaches are reshaping clinical trial regulations to enhance efficiency and adaptability. A recent study by Rosa et al. suggested leveraging real-world data collected through digital technologies for improving clinical trial processes [66]. The study also highlighted the absence of sufficient regulatory frameworks to guide the use of digital tools in clinical trials [66]. The authors argued for the data quality and representativeness, of data that could potentially be sourced to electronic records of study participants in clinical trials thereby simplifying design and collection methods. The advancement and growing need for innovative approaches in clinical trial design calls for clear and well-defined regulatory guidelines in ensuring simpler evidence generation and study implementation. The US Food and Drug Authority (FDA) has responded to this need by establishing the Center for Clinical Trials Innovation (C3TI) primarily to guide and foster integration of innovative approaches to enhance efficiency of drug development in clinical trials [67]. Such proactive measures by regulatory agencies exemplify the potential for improving efficiency in drug development, ultimately making life-saving treatments accessible more quickly.

Furthermore, a study by Scheppler et al. identified the role regulatory authorities play in accelerating global access to life-saving vaccines and advocated for harmonization and collaboration of National regulatory agencies in clinical trial processes [68]. Collaboration among the regulatory agencies is key to helping solve the lengthy drug approval challenge and ultimately help ensure patients receive the safe and effective treatments they deserve.

In Sub-Saharan Africa, a recently ratified collaboration shows the interest of African regulatory agencies in working toward well-regulated clinical trials through the African Medicines Agency (AMA) [69]. Hwenda et al explored the paucity of clinical trial data in Africa - which accounts for less than 3% of global clinical trial genomics data and the readiness of the AMA to accelerate drug development and improve clinical trials in Africa [69]. Africa has untapped potential to contribute to clinical trial data given its 1.3 billion population, diverse population and disease burden [70]. As a regulatory initiative, the AMA is well positioned to improve the continent's contribution to clinical research and innovation by strengthening existing regulatory systems, harmonizing protocols and standards to simplify trial set-up, streamlining trial approvals, and leveraging partnerships such as the European and Development Country Clinical Trial Partnership (EDCTP) to ensure that clinical trials are set up with the participation of the right local partners to maximize successful trials [69]. By addressing the challenges of clinical trial readiness, the AMA could significantly bolster Africa's role in drug development.

3.2. Review and Approval Mechanisms

Drug review and approval mechanisms vary considerably between countries. In the US, FDA relies on preclinical and clinical trial data from drug development to make an approval decision for a New Drug Application (NDA). Each NDA undergoes a thorough review typically lasting for 6 to 10 months to verify new drug efficacy, safety and the adequacy of drug development processes. A decision for approval is passed when the review committee has determined the new drug is safe and effective for intended use. FDA review processes can also be expedited through accelerated approval and priority review pathways which allows faster evaluations of therapies addressing serious or life-threatening conditions such as COVID-19 vaccines [11,71]. The European Commission utilizes a centralized drug review and approval mechanism through the European Medicines Agency (EMA) Committee for Medicinal products for Human Use (CHMP). CHMP provides recommendations after a new drug review and the EC authorizes based on this recommendation [21]. Such a harmonized strategy makes approved medicines accessible to patients in 27 European Union member states and illustrates how centralized strategic approach can accelerate access to new therapies in a timely fashion.

3.3. Challenges in Multinational Clinical Trial Regulations and Potential Solutions

Conducting multinational clinical trials presents significant challenges, as these trials must comply with diverse local and international laws, regulations, and guidelines that differ from one country to another. The incompatibility of these regulatory frameworks, combined with a lack of adequately trained Good Clinical Practice (GCP) staff at clinical sites and difficulties in ensuring effective oversight across different jurisdictions, can result in delays in studying timelines and increased costs.

One potential solution to enhance global collaboration in clinical trials is the creation of a more unified regulatory framework that offers all trial sites a common reference structure for regulatory review and informed consent processes. Such a system would enable national regulators to collaborate on approvals, despite differences in political, social, and economic contexts, while maintaining decentralized oversight within each country. Additionally, establishing a centralized support network could provide mentorship to less experienced researchers and facilitate the exchange of expertise and technology throughout the trial process, addressing challenges related to limited professional expertise and infrastructure.

4. Post-Market Safety Monitoring

4.1. Pharmacovigilance Systems

Pharmacovigilance (PV) systems are an extension of the original adverse drug reaction (ADR) monitoring and reporting systems and are also internationally recognized systems that must align with the entire drug life cycle and post marketing supervision of drugs.

Internationally-recognized Pharmacovigilance (PV) Systems

Various internationally-recognized drug safety surveillance frameworks exist worldwide: the European Union (EU) monitoring network, the World Health Organization (WHO)-Uppsala Monitoring Centre approach, and the International Conference on Harmonization (ICH) system. Despite differences in operational structures and implementations across these three frameworks, they all aim to promote safe medication use [72]. The ten pioneering members of the Uppsala Monitoring Centre include Australia, Canada, the Federal Republic of Germany, Ireland, the Netherlands, New Zealand, Sweden, the United Kingdom, the USA and former Czechoslovakia. These nations were the first to respond to the thalidomide tragedy by establishing medication evaluation committees, creating standardized Adverse Drug Reaction (ADR) documentation forms, and implementing safety protocols [71].

The WHO's global initiative for medication safety surveillance, known as the Programme for International Drug Monitoring (WHO-PIDM), comprises approximately 80 high-income countries. While PV systems require significant financial resources to operate, low- and middle-income countries (LMICs) often struggle with budgetary constraints, leading to limited or non-functional PV systems. In contrast, high-income nations can invest in robust and effective PV activities, demonstrating a direct relationship between a country's income level and its medicine safety measures [71].

4.2. Risk Management and Mitigation

Across the globe, regulatory authorities have prioritized risk assessment as well as risk mitigation strategies [73]. These approaches help ensure continued product safety while maintaining market access.

4.2.1. Risk Management Plan (RMP)

One key guide that applies to risk management involves the development of a Risk Management Plan (RMP) that summarizes product knowledge and target population data at the time of application, encompassing clinical development findings, population epidemiology, disease natural history, and identifying unstudied populations who may receive the drug post-authorization. This information is crucial for assessing post-marketing adverse events and potential risks. While not all identified and potential risks need to be addressed, companies must prioritize significant risks affecting benefit-risk balance through early collaboration between clinical pharmacology, drug development, epidemiology, pharmacovigilance teams, and regulatory agencies [74].

4.2.2. Risk Evaluation and Mitigation Strategy (REMS)

While the EMA mandates a product’s RMP for all applications, the U.S. Food and Drug Administration (FDA) may mandate a Risk Evaluation and Mitigation Strategy (REMS) for certain medications to ensure that benefits outweigh potential risks.

REMS is a drug safety program that the FDA requires for certain medications with serious safety concerns. While all medications have labeling that describes risks, REMS specifically focuses on preventing, monitoring and/or managing serious risks through education and reinforcement of safe medication use behaviors, rather than mitigating all adverse events [75].

REMS focuses on specific strategies that may be outlined in Part V of the RMP, which may include the following: a Medication guide educating patients regarding safety risks and proper product usage; a Communication Plan for healthcare providers regarding safety concerns; and Elements to Assure Safe Use (ETASU), which may restrict product distribution through mechanisms such as requiring prescriber and pharmacist certification, limiting use to inpatient settings, patient monitoring, restricting dispensing to patients with documentation of safe-use conditions, or mandating enrollment in a patient registry [74]. Although the implementation of an RMP and REMS occurs in the post-approval stage, planning and study-design, including development of effective post-approval tools and risk reduction approaches should be established during the pre-approval phase [74].

5. Emerging Challenges and Future Directions

5.1. Advanced Therapy Medicinal Products (ATMPs)

As new and emerging drug–resistant or even untreatable diseases increase, so does the need for innovative therapies, many of which are more advanced in nature compared with existing therapies. These therapies, collectively termed Advanced Therapy Medicinal Products (ATMPs) in the European regulatory context, include gene therapies, cell therapies, and tissue-engineered products, irrespective of their cellular targets, often present novel and complex mechanisms of action [8,76]. Their longer-term effects may be delayed, uncertain, or unknown due to limited data, unlike conventional medications, making it challenging for regulatory authorities especially when considering their entirety of effects, including safety, efficacy, and generational transfection. Ethical concerns surrounding these therapies, especially gene therapies, in terms of their long-term effects have sparked debate and skepticism regarding their acceptance in recent years [77,78].

Recognizing the distinct challenges posed by ATMPs, global regulatory authorities have developed tailored classification systems and approval pathways [63,79]. However, differences in terminology, regulatory structures, and post-marketing requirements persist across regions, potentially delaying patient access and complicating global harmonization efforts [79,80]. International regulatory bodies such as the International Council for Harmonisation (ICH) and the World Health Organization (WHO) have sought to address these gaps by promoting standardization and convergence in regulatory practices [73,81].

Major regulatory agencies have adopted distinct frameworks to govern ATMPs and similar innovative therapies, shaped by differences in regulatory maturity, healthcare infrastructure, and ethical considerations (Table 2).

5.2. Global Health Emergencies

The International Coalition of Medicines Regulatory Authorities (ICMRA) is a voluntary coalition of leaders from medicines regulatory authorities that provides strategic direction to improve communication and enhance effective global crisis response mechanisms. Across the globe, agencies responsible for medicine regulation have established collaborative efforts through ICMRA to accelerate and strengthen processes for developing and approving COVID-19 therapeutics, including preventive vaccines and treatment options; and since October 1st, 2019, leadership of ICMRA has been provided by the EMA’s Executive Director [92]. The coalition acknowledges the World Health Organization’s (WHO) international leadership in managing global health emergencies. Together, ICMRA and WHO encourage pharmaceutical manufacturers to ensure comprehensive access to clinical trial data for novel therapeutics and immunizations - regardless of whether these products receive full authorization, or limited approval, emergency authorization, or are ultimately denied market access [93].

5.2.1. Public Health Emergency of International Concern (PHEIC)

A Public Health Emergency of International Concern (PHEIC) is defined as an extraordinary event that constitutes a public health risk to other states through the international spread of disease and potentially requires a coordinated international response. This phenomenon implies a situation that is serious, sudden, unusual or unexpected; that carries implications for public health beyond the affected State’s national borders; and which may require immediate international action [94].

5.2.2. Examples of Major Scenarios of Global Health Emergencies

• Case Type 1: Quality or safety issues with medicines on the market that affect public health across multiple countries [31]. For example, investigating widespread problems with medication that could be causing harm.
• Case Type 2: Shortage of approved medicines during crises, where previously available products become scarce or unavailable due to supply problems [31]. A clear example is a viral outbreak where antiviral treatments or vaccines are in short supply.
• Case Type 3: Urgent need for new treatments or vaccines during emerging health threats such as the COVID-19 pandemic. These situations typically arise when the WHO declares a Public Health Emergency, prompting national health authorities and WHO to act using existing international health guidelines [31].

To improve coordination between ICMRA members and the WHO, the coalition encourages the WHO to contact ICMRA leadership when regulatory action is needed during global health emergencies [31].

5.3. Case Studies in Regulatory Innovation

COVID-19 Vaccine Development

The recent COVID-19 pandemic was an event that challenged the regulatory authorities worldwide to achieve unprecedented levels of innovation. As the world grappled with the reality of increased deaths from the novel infectious disease, there was a pressing need for treatment options. Table 3 summarizes regulatory processes through which selected agencies approve COVID-19 vaccines in accordance with the WHO Emergency Use Listing (EUL) Procedure for vaccines. In 2021, the FDA approved the first COVID-19 vaccine after adjudging that it met its rigorous scientific standards for emergency use authorization [95,96]. The EMA did the same [97,98]. The successful emergence of the COVID-19 vaccine in record time was based on the utilization of highly adaptable vaccine platforms such as messenger RNA (mRNA) and the adaptation of structural biology tools to design agents (immunogens) that powerfully stimulate the immune system [99]. This decision follows the principle of beneficence, which minimizes risk and maximizes benefits for the sake of promoting health and wellbeing [100].

6. Conclusions

Looking ahead, regulatory authorities worldwide should, more than ever, adopt systems thinking, balancing the need for innovations in disease management with the responsibility of ensuring safety, efficacy, and ethical integrity, while also considering the unintended consequences of novel therapies. These agencies must continue to proactively update and revise regulatory guidelines to meet the demands of an ever-evolving healthcare landscape, including scientific advances and emerging health threats. The distinct regulatory approaches to advanced therapies, as seen across jurisdictions, underscore the urgency of strengthening international dialogue and convergence. As the global population grows and pharmaceutical innovation accelerates, the need for stronger international alliances and harmonization of regulatory authorities becomes even more critical. Such collaboration will be instrumental in supporting effective risk management, promoting equitable access, and enhancing global health security. In this rapidly changing environment, regulatory frameworks must remain agile and forward-looking, capable of addressing new therapeutic models while still fulfilling their core role of protecting public health. International cooperation and harmonization will not just facilitate innovation but will increasingly define the responsiveness of health systems worldwide.